Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
226
-
Total 13F shares, excl. options
-
51.8M
-
Shares change
-
+819K
-
Total reported value, excl. options
-
$3.37B
-
Value change
-
+$47.6M
-
Put/Call ratio
-
1.27
-
Number of buys
-
108
-
Number of sells
-
-108
-
Price
-
$65.18
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2022
259 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2022.
HAEMONETICS CORP - Common Stock (HAE) has 226 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.8M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.28M shares), WELLINGTON MANAGEMENT GROUP LLP (5.64M shares), BlackRock Inc. (5.58M shares), VANGUARD GROUP INC (5.02M shares), Neuberger Berman Group LLC (3.72M shares), STATE STREET CORP (1.67M shares), FRANKLIN RESOURCES INC (1.3M shares), Fisher Asset Management, LLC (1.27M shares), LGT CAPITAL PARTNERS LTD. (988K shares), and GEODE CAPITAL MANAGEMENT, LLC (865K shares).
This table shows the top 226 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.